MIRA INFORM REPORT

Report Date :

11.12.2014

IDENTIFICATION DETAILS

Name :	BRYON PHARMACEUTICAL PVT LTD
Registered Office :	48, Hayatabad Industrial Estate, Peshawar
Country :	Pakistan
Year of Establishments :	1992
Com. Reg. No.:	0027039
Legal Form :	Private Limited Company
Line of Business :	engaged in Manufacturer and Marketing of Pharmaceutical Products such as Antibiotics, Analgesic, Anti-Pyretics, Anti-Psychotic, Anti Ulcers, Anti-Hypertensive, Anti-Thrombosis, Anti-Diabetic, Anti- Histamines, Anti-Asthmatics, Lipid Lowering Agent, Anti-Fungal, Oral Tablets, Capsules, Syrups and Vaginal Inserts
No of Employees :	77

RATING & COMMENTS

MIRA’s Rating :

ba

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory
Payment Behaviour :	No Complaints
Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – September 30, 2014

Country Name	Previous Rating (30.06.2014)	Current Rating (30.09.2014)
Pakistan	b1	b1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Pakistan ECONOMIC OVERVIEW

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment was 6.6% in 2013, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in the following two years, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3.5% per year from 2008 to 2013. Pakistan must address long standing issues related to government sales and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

Source : CIA

Business Name

BRYON PHARMACEUTICAL PVT LTD

Full Address

Registered Address & Factory

48, Hayatabad Industrial Estate, Peshawar, Pakistan

Tel #	92 (91) 5817601, 5817602
Fax #	92 (91) 5816018
Email	bryonmd@psh.paknet.com.pk

Short Description Of Business

a.	Nature of Business	engaged in Manufacturer and Marketing of Pharmaceutical Products such as Antibiotics, Analgesic, Anti-Pyretics, Anti-Psychotic, Anti Ulcers, Anti-Hypertensive, Anti-Thrombosis, Anti-Diabetic, Anti- Histamines, Anti-Asthmatics, Lipid Lowering Agent, Anti-Fungal, Oral Tablets, Capsules, Syrups and Vaginal Inserts
b.	Year Established	1992
c.	Registration #	0027039

Branches

Address	203-B, City Towers, University Road, Peshawar, Pakistan
Tel #	92 (91) 5701029, 5701030
Fax #	92 (91) 5844035

Auditor

Tariq Ayub Anwar & Co.

(Chartered Accountants)

Legal Status

Subject Company was established as a Private Limited Company in 1992

Authorized Capital	Rs. 50,000,000/- divided into 500,000 shares of Rs. 100/- each
Issued & Paid up Capital	Rs. 44,731,000/- divided into 447,310 shares of Rs. 100/- each

Details of Directors

Names	Designation
Mr. Amjad Hussain Siddiqui Mr. Muhammad Jaffar Siddiqui Mr. Mohammad Haroon Siddiqui Mr. Muhammad Shakir Siddiqui Mr. Muhammad Aamir Siddiqui Mst. Sajida Parveen Mr. Muhammad Arshad Anjum Mr. Muhammad Umar Siddiqui Mr. Muhammad Jawad	Chief Executive Director Director Director Director Director Director Director Director

Shareholders

Names

No. of Shares

Mr. Amjad Hussain Siddiqui Mr. Muhammad Jaffar Siddiqui Mr. Mohammad Haroon Siddiqui Mr. Muhammad Shakir Siddiqui Mr. Muhammad Aamir Siddiqui Mst. Sajida Parveen Mr. Muhammad Arshad Anjum Mst. Rakhshanda Amjad Mst. Tasaliat Zaib Mr. Mohammad Ilyas Siddiqui Mst. Faiqa Uzmi Mst. Nazima Haroon Mr. Muhammad Jawad Mr. Muhammad Fawad Mr. Mohammad Ali Siddiqui Mr. Mohammad Umar Siddiqui Mr. Obaidullah Siddiqui Mst. Zakawat Shakir Mst. Fareesa Bano Mr. Mohammad Hamad Mst. Monisa Bano Mst. Ambreen Aamir Mr. Mohammad Nasir Siddiqui Mst. Muziyan Haider Mr. Mohammad Ahsan Siddiqui Miss Fasiha Shakir Miss Hajra Shakir Miss Madiha Shakir Mrs. Sabahat Fawad Mrs. Nadia Jawad

3,647 6,000 85,842 69,477 6,000 5,000 3,000 7,420 6,699 21,865 23,000 8,000 14,750 16,670 30,000 10,000 30,000 21,000 6,820 17,630 8,815 5,000 13,835 5,000 3,000 5,000 5,000 5,000 960 2,880

Associates

A. Subsidiary

None

B. Associated Companies

- Do -

Business Activities

engaged in Manufacturer and Marketing of Pharmaceutical Products such as Antibiotics, Analgesic, Anti-Pyretics, Anti-Psychotic, Anti Ulcers, Anti-Hypertensive, Anti-Thrombosis, Anti-Diabetic, Anti- Histamines, Anti-Asthmatics, Lipid Lowering Agent, Anti-Fungal, Oral Tablets, Capsules, Syrups and Vaginal Inserts

brand names

ALBEN, AZIBECT, CARICARD, CEBRIN, CLOXIDIL, CORLET, CORSAFE, DOXYCLATE, ENPRIL, EPILEX, FLECTIN, FLUCON, GYNOSAFE, LAPRANX, LOKESTROL, LOKIT, LORAGIX, LOSATEN, MAYOFLEX, MYCOLOCK, NIMEROL, NOBETEN, NOBILIUM, NOCER, ORAM, OSTRIN, SYCOCAR, TERBULIN, TYLADOL, ZECLORIN, ZEPEP, ZOLOXIN

Number of Employees

77

Annual Production Volume

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture

Annual Sales Volume

Year	In Pak Rupees
2012	75,000,000/- (Estimated)

Trade Suppliers

(Foreign)

· SARAYU MARITIME PVT LTD, INDIA.

GREAT SOURCES LIMITED, CHINA.

HEER PHARMA (PVT) LIMITED, INDIA.

Distributors Network

Mainly exist at major cities of Khyber Pakhtoonkwa Province of Pakistan

Bankers

(1) Habib Bank Limited, Pakistan.

(2) Standard Chartered Bank, Pakistan.

(3) Bank Alfalah Limited, Pakistan.

(4) Faysal Bank Limited, Pakistan.

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 101.30
UK Pound	1	Rs. 158.25
Euro	1	Rs. 125.10

Comments

Subject Company was established in 1992 and is engaged in manufacture & marketing of Pharmaceutical Products. Overall reputation is normal. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms & conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.61.95
UK Pound	1	Rs.97.16
Euro	1	Rs.76.75

INFORMATION DETAILS

Analysis Done by :	DIV
Report Prepared by :	MNL

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
--	NB	New Business	--

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.